Prion diseases are rare and obligatory fatal
neurodegenerative disorders caused by the accumulation of a misfolded
isoform (PrPSc) of the host-encoded
prion protein (PrPc). Prophylactic and therapeutic regimens against
prion diseases are very limited. To extend such strategies we selected
peptide aptamers binding to PrP from a combinatorial
peptide library presented on the Escherichia coli
thioredoxin A (trxA)
protein as a scaffold. In a yeast two-hybrid screen employing full-length murine PrP (aa 23-231) as a bait we identified three
peptide aptamers that reproducibly bind to PrP. Treatment of
prion-infected cells with recombinantly expressed aptamers added to the culture medium abolished PrPSc conversion with an IC50 between 350 and 700 nM. For expression in eukaryotic cells,
peptide aptamers were fused to an N-terminal
signal peptide for entry of the secretory pathway. The C terminus was modified by a glycosyl-
phosphatidyl-inositol-(GPI) anchoring signal, a KDEL retention motif and the transmembrane and cytosolic domain of LAMP-I, respectively. These
peptide aptamers retained their binding properties to PrPc and, depending on
peptide sequence and C-terminal modification, interfered with endogenous PrPSc conversion upon expression in
prion-infected cells. Notably,
infection of cell cultures could be prevented by expression of KDEL
peptide aptamers. For the first time, we show that trxA-based
peptide aptamers can be targeted to the secretory pathway, thereby not losing the affinity for their target
protein. Beside their inhibitory effect on
prion conversion, these molecules could be used as fundament for rational
drug design.